Pharmaceutical Clinical Research Associates (CRAs) are critical members of the drug development team responsible for managing and monitoring clinical trials that test new medications for safety and efficacy. They ensure that trials are conducted in compliance with regulatory standards such as Good Clinical Practice (GCP) and study protocols. CRAs regularly visit clinical trial sites to verify the accuracy of collected data, confirm that patients meet eligibility criteria, and ensure informed consent has been properly obtained. By meticulously reviewing case report forms against source documents, they help maintain data integrity and protect patient safety throughout the study. Their monitoring activities are essential to producing reliable and valid results for regulatory review.
In addition to site monitoring, CRAs serve as a communication link between pharmaceutical sponsors, clinical investigators, and regulatory authorities. They provide ongoing support and training to clinical site personnel to uphold quality standards and regulatory compliance. CRAs also prepare monitoring visit reports and assist in the preparation of documentation required for audits and inspections. Strong attention to detail, excellent organizational skills, and the ability to manage multiple sites are crucial attributes for success in this role. Ultimately, CRAs help ensure that clinical trials are conducted ethically and efficiently, contributing to the development of new therapies that improve patient outcomes globally.
Title : Medical liver biopsy: Toward a personalized approach
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through design-inspired biotech- & biopharma-driven applications and upgraded business marketing to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Mathematical modeling the disc diffusion test: Antibacterial activity of copper-doped SnO2
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Genetic keys and nano locks: Unlocking personalized medicine
Srividya Narayanan, Northeastern University, United States
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico